Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Size, Share & Trends (2025 - 2030)

The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Report is Segmented by Service Type (API Manufacturing, and More), Molecule Type (Small Molecule, and More), Dosage Form (Solid Oral, Sterile Injectables, and More), Therapeutic Area (Oncology, Metabolic and Endocrine, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market with other markets in Packaging Industry

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Analysis by Mordor Intelligence

The Pharmaceutical contract development and manufacturing organization (CDMO) market size is valued at USD 258.88 billion in 2025 and is projected to reach USD 353.20 billion by 2030, reflecting a 6.41% CAGR. Robust outsourcing demand for complex biologics, the rise of high-potency APIs (HPAPIs), and artificial-intelligence-enabled–enabled process-development platforms underpin this trajectory. Peptide-based GLP-1 therapies, expanding vaccine programs, and sustained investment in digitally connected plants further amplify the need for specialist partners able to absorb capital and regulatory risks. North American innovators continue to anchor high-value biologics and gene-therapy work, while Asia-Pacific cost advantages accelerate capacity expansion. Consolidation—typified by Novo Holdings’ USD 16.5 billion purchase of Catalent—signals a decisive shift toward end-to-end providers that combine development, scale-up, and commercial production.

Key Report Takeaways

  • By service type, API manufacturing held 55.44% of the Pharmaceutical contract development and manufacturing organization (CDMO) market share in 2024, while finished-dosage-form (FDF) development and manufacturing is forecast to expand at 7.42% CAGR through 2030.
  • By molecule type, small-molecule APIs captured 62.34% of the Pharmaceutical contract development and manufacturing organization (CDMO) market size in 2024; HPAPIs are projected to grow at an 8.32% CAGR to 2030.
  • By dosage form, solid orals accounted for 40.23% share of the Pharmaceutical contract development and manufacturing organization (CDMO) market size in 2024, whereas sterile injectables are advancing at 9.32% CAGR.
  • By therapeutic area, oncology commanded 32.43% revenue share in 2024, while infectious-disease and vaccine projects post the fastest 8.42% CAGR outlook.
  •  By geography, North America led with 38.43% of the Pharmaceutical contract development and manufacturing organization (CDMO) market share in 2024; Asia-Pacific records the highest 7.42% CAGR projection.

Segment Analysis

By Service Type: API Manufacturing Remains the Anchor

Active Pharmaceutical Ingredient (API) Manufacturing is the largest segment in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market, holding a significant market share of approximately 68% in 2023. This segment is pivotal due to its role in the production of essential components for pharmaceutical drugs, which are critical for the healthcare industry. The dominance of this segment is driven by the increasing demand for APIs, particularly for small molecule drugs, which constitute a major portion of the pharmaceutical market. Technological advancements in API synthesis and the growing trend of outsourcing API production to specialized CDMOs have further bolstered this segment's growth. Additionally, the rising prevalence of chronic diseases and the need for innovative therapies have amplified the demand for high-quality APIs. The segment also benefits from stringent regulatory requirements, which encourage pharmaceutical companies to partner with experienced CDMOs for API manufacturing. Overall, the API manufacturing segment remains a cornerstone of the CDMO market, driving innovation and ensuring the availability of critical pharmaceutical ingredients.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Molecule Type: Small Molecules Hold Scale; HPAPIs Accelerate

Small molecules captured 62.34% of 2024 value, aided by mature regulatory pathways and broad therapeutic applicability. Reaction-efficiency gains and green-chemistry mandates encourage hybrid batch-continuous plants that drive cost competitiveness. However, oncology’s migration toward antibody-drug conjugates, selective degrader molecules, and micro-dosed cytotoxics pushes HPAPIs to an 8.32% CAGR. CDMOs retrofit suites with negative-pressure isolators and closed-handling skids to comply with <1 μg/m³ OEL thresholds.

The Pharmaceutical contract development and manufacturing organization (CDMO) market size devoted to HPAPIs is forecast to double over the next five years as peptide-based GLP-1s and next-gen chemotherapeutics move through Phase III. HPAPI projects typically command 25-30% pricing premiums due to containment and analytical complexity, supporting higher margins for specialized providers.

By Dosage Form: Solid Orals Dominate; Sterile Injectables Surge

Solid oral products retained 40.23% share in 2024. Robust tableting lines, wet-granulation flexibility, and unrivaled patient acceptance anchor this format. Efforts to extend franchise exclusivity via abuse-deterrent coatings and multiparticulate capsules sustain demand in mature markets. Further, fixed-dose combinations for metabolic disease streamline adherence.

Sterile injectables register the fastest 9.32% CAGR on the back of biologics, long-acting antipsychotics, and biosimilar launches. The Pharmaceutical contract development and manufacturing organization (CDMO) market size for sterile fill-finish is projected to eclipse USD 70 billion by 2030 as dual-chamber syringes, auto-injectors, and lyophilized vials gain regulatory approvals. Simtra BioPharma’s USD 250 million expansion highlights capital intensity and the allure of premium parenteral margins[2]Simtra BioPharma, “Sterile Fill-Finish Expansion,” simtra.com.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Therapeutic Area: Oncology Retains the Lead; Vaccines Rise

Oncology accounted for 32.43% of 2024 CDMO revenue, reflecting high value per gram and constant pipeline replenishment. HPAPI suites, single-use perfusion bioreactors, and conjugation lines support small-batch precision medicines. Demand spikes for checkpoint inhibitors and radioligand therapies keep capacity tight and prices firm.

Infectious-disease and vaccine programs grow at 8.42% CAGR. Government pandemic-preparedness funding exemplified by Moderna’s USD 590 million H5N1 mRNA contract—sustains lipid-nanoparticle-formulation and aseptic-fill investments [3]Moderna, “Moderna Receives $590 Million US Government Contract,” modernatx.com. Expanded adult immunization schedules and antimicrobial-resistance initiatives diversify volumes beyond COVID-19 boosters. Meanwhile, GLP-1–driven endocrine products accelerate metabolic-disorder output, further crowding HPAPI slots.

Geography Analysis

North America retained 38.43% revenue share in 2024, buoyed by premier biologics programs, FDA Orphan-Drug incentives, and a deep venture-capital pool. The United States sustains premium pricing as cGMP compliance costs and stringent data-integrity audits elevate barriers to entry. Canada benefits from free-trade access and skilled resources, whereas Mexico lures secondary packaging and regional solid-oral projects. Thermo Fisher’s USD 4.1 billion filtration-business acquisition reinforces North American vertical-integration strategies.
Asia-Pacific logs the fastest 7.42% CAGR through 2030. China and South Korea bankroll mega-plants for mAbs and oligonucleotides, though geopolitical risk nudges US sponsors toward India and Southeast Asia. The Pharmaceutical contract development and manufacturing organization (CDMO) market size in India alone could surpass USD 22 billion by 2035, aided by PLI incentives and harmonized quality standards.Samsung Biologics’ fourth plant, topping 600,000 L, cements Incheon as the world’s largest single-site biologics hub. Australia leverages expedited regulatory pathways for early-phase oncology and cell-therapy trials.

Europe presents steady expansion anchored in quality leadership. Germany’s continuous-manufacturing clusters and the United Kingdom’s advanced-therapy corridor offset Brexit friction through mutual-recognition waivers. The EMA’s updated variation fees raise short-term compliance costs but assure global sponsors of consistent review rigor. Eastern Europe gains traction as an overflow destination for solid-oral generics and secondary packaging. Sustainability regulations incentivize solvent-recovery units and low-energy lyophilization, driving process innovation.

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The CDMO market is characterized by a high degree of competition and ongoing consolidation, reflecting current CDMO market trends. Global players are expanding their operations in key regions, while local firms are enhancing their capabilities to compete internationally. Mergers and acquisitions are a common strategy, enabling companies to broaden their service offerings and geographical reach. Investment in advanced manufacturing technologies, such as continuous manufacturing and digital integration, is also prevalent, driving CDMO industry growth.
Niche disruptors leverage continuous flow, micro-reactor scale-out, and on-demand formulation to serve precision-medicine pipelines with batch sizes in the tens of grams. Capacity shortages in HPAPI and viral-vector fill-finish create price elasticity that rewards early movers. Competitive intensity will heighten as digital-native entrants compress tech-transfer cycles and as large pharma refines multi-sourcing frameworks to mitigate geopolitical risk.

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Industry Leaders

  1. Catalent Inc.

  2. Recipharm AB

  3. Jubilant Pharmova Ltd

  4. Patheon Inc. (Thermo Fisher Scientific Inc.)

  5. Boehringer Ingelheim Group

  6. *Disclaimer: Major Players sorted in no particular order
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • February 2025: Boehringer Ingelheim and DotBio form a tri-specific-antibody alliance, with Bora Biologics providing cGMP supply.
  • January 2025: Boehringer Ingelheim and DotBio form a tri-specific-antibody alliance, with Bora Biologics providing cGMP supply.
  • December 2024: Novo Holdings closes USD 16.5 billion Catalent deal, creating the world’s largest CDMO platform.
  • November 2024: Avid Bioservices agrees to USD 1.1 billion buyout by GHO Capital and Ampersand, illustrating sustained private-equity appetite

Table of Contents for Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Industry Report

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET LANDSCAPE

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing outsourcing volume by large pharmaceutical companies
    • 4.2.2 Surge in biologics and complex-molecule pipelines
    • 4.2.3 Cost- and speed-advantage of manufacturing in emerging markets
    • 4.2.4 Consolidation toward end-to-end one-stop CDMOs
    • 4.2.5 AI-enabled rapid process-development platforms
    • 4.2.6 GLP-1 and peptide HPAPI capacity build-outs
  • 4.3 Market Restraints
    • 4.3.1 Stringent multi-region regulatory requirements
    • 4.3.2 Capacity-utilization and lead-time risk
    • 4.3.3 High capex for sterile biologics suites
    • 4.3.4 Scarcity of skilled aseptic-manufacturing talent
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
    • 4.6.1 Dosage-formulation technologies
    • 4.6.2 3D printing applications in OSD
    • 4.6.3 Continuous-manufacturing adoption
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Bargaining Power of Suppliers
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Threat of New Entrants
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry
  • 4.8 Investment and Funding Landscape

5. MARKET SIZE AND GROWTH FORECASTS (VALUE)

  • 5.1 By Service Type
    • 5.1.1 API Manufacturing
    • 5.1.1.1 Small Molecule
    • 5.1.1.2 Large Molecule
    • 5.1.1.3 High-Potency (HPAPI)
    • 5.1.2 FDF Development and Manufacturing
    • 5.1.2.1 Solid Dose
    • 5.1.2.2 Liquid Dose
    • 5.1.2.3 Injectable Dose
    • 5.1.3 Secondary Packaging
  • 5.2 By Molecule Type
    • 5.2.1 Small Molecule
    • 5.2.2 Large Molecule (Biologics and Biosimilars)
    • 5.2.3 High-Potency APIs
  • 5.3 By Dosage Form
    • 5.3.1 Solid Oral
    • 5.3.2 Sterile Injectables
    • 5.3.3 Topicals and Transdermals
    • 5.3.4 Specialty/Novel (e.g., ODT, Long-acting)
  • 5.4 By Therapeutic Area
    • 5.4.1 Oncology
    • 5.4.2 Metabolic and Endocrine
    • 5.4.3 Cardiovascular
    • 5.4.4 CNS and Psychiatry
    • 5.4.5 Infectious Diseases and Vaccines
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Russia
    • 5.5.2.7 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia and New Zealand
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 Middle East
    • 5.5.4.1.1 United Arab Emirates
    • 5.5.4.1.2 Saudi Arabia
    • 5.5.4.1.3 Turkey
    • 5.5.4.1.4 Rest of Middle East
    • 5.5.4.2 Africa
    • 5.5.4.2.1 South Africa
    • 5.5.4.2.2 Nigeria
    • 5.5.4.2.3 Egypt
    • 5.5.4.2.4 Rest of Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Market Concentration
  • 6.2 Strategic Moves
  • 6.3 Market Share Analysis
  • 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
    • 6.4.1 Thermo Fisher Scientific Inc. (Patheon)
    • 6.4.2 Lonza Group
    • 6.4.3 Catalent Inc.
    • 6.4.4 Samsung Biologics Co. Ltd.
    • 6.4.5 WuXi AppTec Inc.
    • 6.4.6 Recipharm AB
    • 6.4.7 Jubilant Pharmova Ltd.
    • 6.4.8 Boehringer Ingelheim Group
    • 6.4.9 Pfizer CentreOne
    • 6.4.10 Aenova Holding GmbH
    • 6.4.11 Fujifilm Diosynth Biotechnologies
    • 6.4.12 Baxter BioPharma Solutions
    • 6.4.13 Corden Pharma GmbH
    • 6.4.14 AbbVie Contract Manufacturing
    • 6.4.15 Cambrex Corporation
    • 6.4.16 Syneos Health Inc.
    • 6.4.17 IQVIA Holdings Inc.
    • 6.4.18 Labcorp Drug Development
    • 6.4.19 PAREXEL International Corporation
    • 6.4.20 ICON PLC
    • 6.4.21 Charles River Laboratories International Inc.
    • 6.4.22 Eurofins Scientific SE
    • 6.4.23 SGS Life Science Services SA
    • 6.4.24 CMIC Holdings Co. Ltd
    • 6.4.25 Novotech Pty Ltd
    • 6.4.26 Hangzhou Tigermed Consulting Co. Ltd
    • 6.4.27 Samsung Bioepis Co. Ltd
    • 6.4.28 Tesa Labtec GmbH (TESA SE)
    • 6.4.29 Tapemark
    • 6.4.30 Famar SA

7. MARKET OPPORTUNITIES AND FUTURE OUTLOOK

  • 7.1 White-space and Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Report Scope

The study tracks and analyzes the demand for outsourcing CMO and CRO activities within the pharmaceutical industry based on the current trends and market dynamics. The market numbers are derived by tracking the revenue generated by the players operating in the market who are providing CRO & CMO services. The study provides a detailed breakdown of various research phases and service types. This report analyzes the factors based on the prevalent base scenarios, key themes, and end-user vertical-related demand cycles.

The pharmaceutical contract development and manufacturing organization market is segmented by service type CMO segment (active pharmaceutical ingredient (API) manufacturing (small molecule, large molecule, and high potency (HPAPI)), finished dosage formulation (FDF) development and manufacturing (solid dose formulation (tablets), liquid dose formulation, injectable dose formulation), secondary packaging), research phase CRO segment (pre-clinical, phase I, phase II, phase III, phase IV), pharmaceutical CMO geography (North America [United States, Canada], Europe [United Kingdom, Germany, France, Italy, and Rest of Europe], Asia-Pacific [China, India, Japan, Australia, and the Rest of Asia-Pacific], Latin America [Brazil, Mexico, Argentina, and the Rest of Latin America], and the Middle East and Africa [United Arab Emirates, Saudi Arabia, South Africa, and the Rest of Middle-East and Africa]), and pharmaceutical CRO geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa). The market sizes and forecasts are provided in terms of value USD for all the above segments.

By Service Type API Manufacturing Small Molecule
Large Molecule
High-Potency (HPAPI)
FDF Development and Manufacturing Solid Dose
Liquid Dose
Injectable Dose
Secondary Packaging
By Molecule Type Small Molecule
Large Molecule (Biologics and Biosimilars)
High-Potency APIs
By Dosage Form Solid Oral
Sterile Injectables
Topicals and Transdermals
Specialty/Novel (e.g., ODT, Long-acting)
By Therapeutic Area Oncology
Metabolic and Endocrine
Cardiovascular
CNS and Psychiatry
Infectious Diseases and Vaccines
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Russia
Rest of Europe
Asia-Pacific China
India
Japan
South Korea
Australia and New Zealand
Rest of Asia-Pacific
Middle East and Africa Middle East United Arab Emirates
Saudi Arabia
Turkey
Rest of Middle East
Africa South Africa
Nigeria
Egypt
Rest of Africa
South America Brazil
Argentina
Rest of South America
By Service Type
API Manufacturing Small Molecule
Large Molecule
High-Potency (HPAPI)
FDF Development and Manufacturing Solid Dose
Liquid Dose
Injectable Dose
Secondary Packaging
By Molecule Type
Small Molecule
Large Molecule (Biologics and Biosimilars)
High-Potency APIs
By Dosage Form
Solid Oral
Sterile Injectables
Topicals and Transdermals
Specialty/Novel (e.g., ODT, Long-acting)
By Therapeutic Area
Oncology
Metabolic and Endocrine
Cardiovascular
CNS and Psychiatry
Infectious Diseases and Vaccines
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Russia
Rest of Europe
Asia-Pacific China
India
Japan
South Korea
Australia and New Zealand
Rest of Asia-Pacific
Middle East and Africa Middle East United Arab Emirates
Saudi Arabia
Turkey
Rest of Middle East
Africa South Africa
Nigeria
Egypt
Rest of Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the pharmaceutical contract development and manufacturing organization (CDMO) market?

The Pharmaceutical CDMO market size stands at USD 258.88 billion in 2025 and is projected to reach USD 353.20 billion by 2030, reflecting a 6.41% CAGR.

Which CDMO service segment generates the greatest revenue today?

API manufacturing leads with 55.44% of 2024 revenue, supported by entrenched small-molecule infrastructure and rising demand for high-potency APIs.

Which region holds the largest market share and which is expanding the quickest?

North America captured 38.43% of 2024 global revenue, while Asia-Pacific records the fastest 7.42% CAGR thanks to cost advantages and large-scale capacity additions.

How are high-potency APIs (HPAPIs) and sterile injectables performing?

HPAPIs expand at an 8.32% CAGR, propelled by oncology and targeted-therapy pipelines, and sterile injectables advance at a 9.32% CAGR on the back of biologics and vaccine demand.

What is the fastest-growing service category?

Finished-dosage-form (FDF) development and manufacturing posts the highest 7.42% CAGR through 2030 as drug sponsors seek patient-centric formats and accelerated life-cycle management.

Page last updated on: July 11, 2025